You're contacting media contact of this press release
Title: Andarix Pharmaceuticals CEO to Present on Targeted Radiometal Therapeutics for Lung Cancer at International Symposium on Bioorganometallic Chemistry 2025
Boston, MA, United States, 21st Aug 2025 – Andarix Pharmaceuticals, a clinical‑stage biopharmaceutical company developing next‑generation targeted radiotherapeutics for oncology, today announced that Chief Executive Officer Chris Adams will present at the upcoming International Symposium on Bioorganometallic Chemistry (ISBOMC) 2025, taking place August 26–29, 2025, in Paris, France.Mr. Adams will highlight Andarix’s innovative approach to targeted radiometal-based therapeutics designed to treat lung cancer, focusing on the company’s proprietary delivery platforms that combine the precision of biologically targeted ligands with the therapeutic power of radiometals. The presentation will outline recent preclinical and translational research data underscoring the potential of these agents to address the high unmet medical need in patients with advanced lung cancer.Presentation Details:Conference: International Symposium on Bioorganometallic Chemistry (ISBOMC) 2025Date: August 26–29, 2025Location: Paris, FrancePresenter: Chris Adams, CEO, Andarix Pharmaceuticals[Insert exact date/time of presentation when available]“Andarix is committed to advancing targeted radiotherapeutics that deliver highly potent treatments directly to cancer cells, while sparing normal tissues,” said Chris Adams, CEO of Andarix Pharmaceuticals. “We are excited to share our progress with the scientific community at ISBOMC 2025, a leading forum for advancing the field of bioorganometallic chemistry.”About Andarix PharmaceuticalsAndarix Pharmaceuticals is a biopharmaceutical company pioneering targeted radiotherapeutics for oncology using proprietary radiometal conjugate technology. By combining precision targeting with the proven efficacy of radiotherapy, Andarix is developing a pipeline of novel thera...
This press release is issued by King Newswire